无容量
医学
内科学
危险系数
胃肠病学
生物标志物
癌症
临床试验
肿瘤科
免疫疗法
置信区间
生物化学
化学
作者
Hisato Kawakami,Yu Sunakawa,Eisuke Inoue,Ryo Matoba,Kenta Noda,Toshiyuki Sato,Chihiro Suminaka,Mami Yamaki,Yasuhiro Sakamoto,Ryohei Kawabata,Atsushi Ishiguro,Yusuke Akamaru,Yosuke Kito,Hiroshi Yabusaki,Jin Matsuyama,Mutsuo Takahashi,Akitaka Makiyama,Hidetoshi Hayashi,Kenji Chamoto,Tasuku Honjo,Kazuhiko Nakagawa,Wataru Ichikawa,Masashi Fujii
标识
DOI:10.1016/j.ejca.2023.02.003
摘要
The clinical value of soluble forms of programmed cell death-1 (sPD-1), PD ligand 1 (sPD-L1) and cytotoxic T lymphocyte-associated protein-4 (sCTLA-4) for gastric cancer (GC) patients treated with nivolumab monotherapy has remained unknown.Blood samples collected before nivolumab treatment from 439 GC patients enrolled in the DELIVER (Japan Clinical Cancer Research Organisation GC-08) trial were analysed for sPD-1, sPD-L1 and sCTLA-4. Corresponding baseline clinical data were also retrieved.Higher plasma levels of sPD-1 (hazard ratio [HR] = 1.27, p = 0.020), sPD-L1 (HR = 1.86, p < 0.001) and sCTLA-4 (HR = 1.33, p = 0.008) were significantly associated with shorter overall survival (OS), whereas only higher sPD-L1 levels was significantly associated with shorter progression-free survival (HR = 1.30, p = 0.008). The sPD-L1 concentration was significantly associated with the Glasgow prognostic score (GPS) (p < 0.001), but both sPD-L1 (HR = 1.67, p < 0.001) and GPS (HR = 1.39, p = 0.009 for GPS 0 versus 1; HR = 1.95, p < 0.001 for GPS 0 versus 2) were independently associated with OS. Patients with a GPS of 0 and low sPD-L1 thus showed the longest OS (median, 12.0 months) and those with a GPS of 2 and high sPD-L1 showed the shortest OS (median, 3.1 months), yielding a HR of 3.69 (p < 0.001).Baseline sPD-L1 levels have the potential to predict survival for advanced GC patients treated with nivolumab, with the prognostic accuracy of sPD-L1 being improved by its combination with GPS.
科研通智能强力驱动
Strongly Powered by AbleSci AI